TY - JOUR
T1 - Hypercholesterolemia and cardiovascular disease
T2 - Focus on high cardiovascular risk patients
AU - Watts, Gerald F.
AU - Catapano, Alberico L.
AU - Masana, Luis
AU - Zambon, Alberto
AU - Pirillo, Angela
AU - Tokgözoglu, Lale
PY - 2020/12
Y1 - 2020/12
N2 - The widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have reviewed the LDL-C goals and recommend an LDL-C reduction of at least 50% and a goal of
AB - The widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have reviewed the LDL-C goals and recommend an LDL-C reduction of at least 50% and a goal of
KW - Cardiovascular disease
KW - High risk patients
KW - Hypercholesterolemia
UR - http://www.scopus.com/inward/record.url?scp=85100692162&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosissup.2021.01.006
DO - 10.1016/j.atherosclerosissup.2021.01.006
M3 - Article
C2 - 33589221
AN - SCOPUS:85100692162
SN - 1567-5688
VL - 42
SP - e30-e34
JO - Atherosclerosis Supplements
JF - Atherosclerosis Supplements
ER -
